GV, a venture capital firm, F-Prime, a global venture capital firm, and Casdin Capital, an investment company, led a $49m Series A funding round in Leyden Labs, a developer of preventive medicines designed to target respiratory viruses. “The speed of development of vaccines during the current pandemic has been impressive, but major global health and economic challenges are evident. If we can develop products that provide immediate protection against existing, mutating and new viruses, we can prevent future pandemics, fight existing ones, and help people strive for a fantastic life. We pursue this critical and ambitious mission with a great team of seasoned and curious biotech leaders and scientists," Koenraad Wiedhaup, Leyden Labs Founder and CEO.